The abstract is read at the publisher; the summary is JClub's.
In vivo CAR T-cell therapy in relapsed or refractory multiple myeloma is linked to deep responses and measurable residual disease negativity after BCMA-directed treatment, with durability shaped by host context.
- Why it matters: The field needs clearer determinants of response because the therapy is generated inside the patient, so efficacy and safety may reflect delivery-system and host immune interactions, not only CAR T-cell activity.
- What they did: This review summarizes clinical data and identifies response determinants to optimize durable translation, focusing on multiple myeloma and drawing on autoimmune applications.
- The result: By separating early benefit attributable to CAR T-cell activity from benefit shaped by biological conditions, trials can better interpret outcomes and guide optimization for durable translation.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.